Teva says real — world data show UZEDY cuts schizophrenia patients’ monthly healthcare costs by USD 1,036.70 vs PP1m
Teva disclosed new real-world studies on UZEDY at Psych Congress, with results already presented during the Sept. 15-19, 2026 meeting. Data in schizophrenia showed UZEDY kept more patients on therapy than competing long-acting injectables, supporting stronger treatment continuity. Patients on UZEDY recorded fewer emerg